ID,Age,Sex,Disease,BM disease burden,Bone marrow cellularity,extramedullary mass,extranodal involvement,B symptoms,Ann Arbor stage,Number of prior therapy lines,Prior hematopoietic stem cell,Prior CAR-T therapy,Bridging therapy,CAR-T therapy following auto-HSCT,Costimulatory molecule,Type of construct(tandem/single target),CAR-T cell infusion date,CRS grade,ICANS grade,Early ICAHT grade,Late ICAHT grade,Infection grade
1,58,0,B-NHL,57.0,3,0,1,0,4,1,HSCT_No_Prior,1,1,0,41BB+CD28,Tandem,2024-05-20,0,0,1,0,0
2,57,0,B-NHL,0.0,1,0,2,0,1,3,HSCT_Autologous,1,0,0,41BB,Single,2024-05-20,0,0,2,2,0
3,46,0,B-NHL,72.82,4,1,2,1,2,2,HSCT_Allogeneic,1,1,1,41BB+CD28,Cocktail,2024-06-02,0,0,2,,3
4,35,1,ALL,0.0,2,0,0,0,3,4,HSCT_Allogeneic,1,1,1,41BB+CD28,Tandem,2024-06-24,1,0,3,3,3
5,41,0,B-NHL,0.11,0,1,2,1,,4,HSCT_Autologous,1,0,0,41BB+CD28,Tandem,2024-06-01,2,0,1,2,3
